Clinical trials: Carcinoma, Hepatocellular
Hepatocellular Carcinoma
Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma
This study will evaluate the safety, efficacy, and activity of patupilone in patients with advanced unresectable and/or metastatic hepatocellular carcinoma based on tumor response using modified RECIST criteria.
- Trial name
- NCT00273312
- Testing
- Patupilone
- Where
- 7 sites in United States, Hong Kong and 2 more
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
HCC, Genetic Predisposition
Understanding Gene ENvironment Interaction in ALcohol-related Hepatocellular Carcinoma
It has been estimated that alcohol causes around 40% of premature liver deaths in Europe each year, although this number is probably underestimated.
- Trial name
- GENIAL (NCT07272200)
- Testing
- quantify of risk factors
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Hepatocellular Carcinoma, Perfusion Scanner
Contribution of the Perfusion Scanner in the Prediction of the Tumor Control of Patients With Hepatocellular Carcinoma Treated With Sorafenib.
Hepatocellular carcinoma (HCC) is a hypervascular tumor. The reference treatment of advanced forms of stage C according to the Barcelona classification (BCLC C) is sorafenib, a multi-target tyrosine kinase inhibitor with…
- Trial name
- HCC-CTPerf (NCT03140332)
- Testing
- Scannographic evaluation of the tumor response performed with mRECIST criteria after 3 months of treatment with sorafenib
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Hepatocellular Carcinoma, Metastatic Cancer
Holmium-166 Retrospective Collection of Real-World Data
The primary objective of the study is to further describe the general safety and clinical performance of QuiremSpheresTM Holmium-166 Microspheres and QuiremScoutTM Holmium-166 Microspheres in a real-world post-market setting…
- Trial name
- RECORD (NCT05111795)
- Testing
- Selective Internal Radiation Therapy with QuiremSpheresTM Holmium-166 Microspheres
- Where
- 12 sites in Belgium, Germany and 5 more
- Volunteers
- 146 people
- Sponsor
- Terumo Europe N.V.
Hepatocellular Carcinoma, Solid Tumor, Adult
Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs
To study the safety and clinical effect of injection of drug-eluting microspheres with multiple chemodrug and/or protein drugs into advanced solid tumors.
- Trial name
- NCT04770207
- Testing
- Injection of drug-eluting microspheres with multiple drugs into solid tumors
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Liver Cancer, Portal Vein Thrombosis
TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis
Therasphere will be administered via catheter through the Hepatic Artery to treat patients with Hepatocellular Carcinoma and Portal vein Thrombosis.
- Trial name
- NCT01556282
- Testing
- TheraSphere
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Emory University
Primary Liver Cancer
Exploring the Application of 3D Bioprinting for Personalized Treatment in Primary Liver Cancer With Tumor Microenvironment
Primary liver cancer, predominantly hepatocellular carcinoma (HCC), represents a major global health burden, with high incidence and mortality rates.
- Trial name
- NCT07437859
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Fibrolamellar Carcinoma, Fibrolamellar Liver Cancer
Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
There is no effective standard treatment for fibrolamellar liver cancer that cannot be removed by surgery. The investigators want to find out what effects, good and/or bad, 3 drugs called letrozole, leuprolide and everolimus will…
- Trial name
- NCT01642186
- Testing
- everolimus, letrozole plus leuprolide, combination of everolimus, letrozole and leuprolide
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma
Safety and Efficacy of IPM001 in Patients With Advanced Hepatocellular Carcinoma
In this study, safety and effects of IPM001 injection on human hepatocellular carcinoma are going to be investigated, IPM001 is a multiple tumor-associated antigen (TAA) and neoantigen/tumor-specific antigen (TSA) sensitized…
- Trial name
- NCT05536427
- Testing
- IPM001
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Peking Union Medical College Hospital
Hepatocellular Carcinoma (HCC), Downstaging
Radiomics Subtyping to Guide Surgery vs. Maintenance Therapy After HCC Downstaging
The goal of this observational study is to learn about the long-term treatment outcomes for patients with initially unresectable hepatocellular carcinoma (HCC) who achieve successful downstaging with the combination therapy of…
- Conditions
- Hepatocellular Carcinoma (HCC), Downstaging, Liver Resection, Lenvatinib
- Trial name
- NCT07581769
- Testing
- Liver resection, TACE plus Lenvatinib and PD1 inhibiter
- Where
- 2 sites in China
- Volunteers
- 500 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma
Carbon Ion Radiotherapy for the Treatment of Chinese Hepatocellular Carcinoma
The aim of this research project is to assess the feasibility and safety of carbon-ion radiotherapy for the treatment of localized Chinese hepatocellular carcinoma
- Trial name
- NCT02802124
- Testing
- carbon-ion radiotherapy for tumor away from GI, carbon-ion radiotherapy for tumor adjacent to GI
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Proton and Heavy Ion Center
Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
This phase II trial is studying how well MD2206 works in treating patients with advanced refractory biliary cancer that cannot be removed by surgery.
- Conditions
- Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma, Recurrent Gallbladder Carcinoma
- Trial name
- NCT01425879
- Testing
- Akt Inhibitor MK2206, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 8 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Hepatic Lesion
Superb Micro-vascular Imaging for Evaluation of Hepatic Lesions
Superb Micro-vascular Imaging (SMI) based on the iBeam platform is used to evaluate the blood supply of solid tumors. Compared with color Doppler technology, the sensitivity, accuracy and consistency of the ability of SMI to…
- Trial name
- NCT04917354
- Testing
- Superb-Microvascular imaging
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
HBV, Primary Liver Cancer
Single-cell RNA Sequencing Resolves the Regulatory Role of HBV on the Hepatocellular Carcinoma Immune Microenvironment
In summary, with the help of single-cell sequencing technology, this study aims to focus on elucidating the influence of HBV-induced hepatocellular carcinoma cell metabolic changes on microenvironment remodeling.
- Trial name
- NCT05677724
- Testing
- HBV DNA Sequencing
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fubing Wang
Hepatocellular Carcinoma Stage IIIB, Cholangiocarcinoma, Intrahepatic
Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment
This trial is to evaluate the palliative effects of colchicine on primary hepatic malignancy using the Department of Health R.O.C. approved doses and methods of administration.
- Conditions
- Hepatocellular Carcinoma Stage IIIB, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma; With Hepatocellular Carcinoma, Hepatocellular Carcinoma Stage IV
- Trial name
- NCT04264260
- Testing
- Colchicine Tablets
- Where
- Taiwan
- Volunteers
- 42 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Hepatocellular Carcinoma
Recurrence of Hepatocellular Carcinoma
analysis of the risk factors of intra-hepatic distant recurrence (IDR) of hepatocellular carcinoma within 1 year after radiofrequency ablation.
- Trial name
- NCT01520779
- Where
- Egypt
- Volunteers
- 99 people
- Sponsor
- Ain Shams University
Hepatocellular Carcinoma
GPC3-CAR-T Cells for the Hepatocellular Carcinoma
This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of GPC3-CAR-T cells in patients with hepatocellular carcinoma.
- Trial name
- NCT04506983
- Testing
- GPC3-CAR-T cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Hepatocellular Carcinoma Resectable, Surgery
Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
The aim of this study was to compare the accuracy of ctDNA-MRD longitudinal surveillance model and internationally accepted pathological MVI results in predicting recurrence after radical hepatectomy.
- Conditions
- Hepatocellular Carcinoma Resectable, Surgery, Recurrence
- Trial name
- NCT06449846
- Testing
- circulating tumor cell DNA detection
- Where
- 4 sites in China
- Volunteers
- 152 people
- Sponsor
- Zhujiang Hospital
Carcinoma
Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.
The purpose of this study is to compare treatment with RAD001 plus best supportive care (BSC) to placebo plus BSC in patients with advanced HCC whose disease progressed while on or after sorafenib treatment or who are intolerant…
- Trial name
- EVOLVE-1 (NCT01035229)
- Testing
- Everolimus, Best Supportive Care (BSC)
- Where
- 131 sites in United States, Australia and 16 more
- Volunteers
- 546 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma, Hepatocellular Cancer
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies
Background: A new cancer treatment takes a person s own T cells, modifies them in a laboratory so they can better fight cancer cells, and then gives them back to the person.
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT05003895
- Testing
- Cyclophosphamide, CAR-T cell, Fludarabine
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.